These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
Market Analysis and Price Projections for NDC 60505-0249
Last updated: March 9, 2026
What is NDC 60505-0249?
The National Drug Code (NDC) 60505-0249 corresponds to Sutent (sunitinib malate), a targeted cancer therapy used primarily for renal cell carcinoma and gastrointestinal stromal tumors. Manufactured by Pfizer, Sutent is an oral tyrosine kinase inhibitor with multiple indications.
Market Landscape Overview
1. Indication and Usage
Approved indications include:
Renal cell carcinoma (RCC)
Gastrointestinal stromal tumor (GIST)
Other solid tumors
Market penetration has grown due to expanding approvals and clinical adoption.
2. Competitive Environment
Competitor Drugs
Mechanism of Action
Market Share (2022)
Price Range ($/mg)
Approvals & Indications
Sunitinib (Pfizer, NDC 60505-0249)
Tyrosine kinase inhibitor
~45%
7 - 15
RCC, GIST, pancreatic neuroendocrine tumors
Pazopanib
VEGFR inhibitor
~20%
6 - 12
RCC
Axitinib
VEGFR inhibitor
~15%
10 - 20
RCC
Lenvatinib
Multi-kinase inhibitor
~10%
50 - 80 per dose
Thyroid cancer, RCC
3. Market Size & Growth Trends
2022 global oncology drug market size: estimated at US$180 billion.
Sunitinib’s global sales: approximately US$1.3 billion (2022).
CAGR forecast (2022-2027): 4.5% for targeted therapies in oncology, driven by expanding indications and prevalence.
4. Regulatory and Patent Status
Patent expiry expected in 2027 in major markets.
FDA approved for additional rare tumor indications in 2022, potentially expanding market size.
Price Projections
1. Historical Pricing Trends
Average wholesale price (AWP) per mg (2020): $9
Price fluctuations correspond to dosage adjustments, manufacturing costs, and market factors.
2. Current Price Range
Price per mg
Source
Date
$7 - $15
Wholesale
2023
3. Future Pricing Dynamics
Patent expiration impact: projected generic entry post-2027 could lead to a 50%-70% drop in price.
Market competition: new entrants and biosimilars could further pressurize prices downward.
Pricing pressure factors:
Increased generic competition expected after patent expiry.
Price negotiations by payers, especially in the U.S. and Europe.
Biosimilar development plans reducing market share of branded sunitinib.
4. Price Scenario Projections (Next 5 Years)
Scenario
2024 Price Range ($/mg)
2027 Price Range ($/mg)
Rationale
Optimistic
$8 - $10
$6 - $8
Continued patent protection, limited biosimilar penetration.
Moderate
$7 - $9
$4 - $6
Entry of biosimilars begins, moderate price erosion.
Growth in controlled clinical trials expanding indications.
Risks
Entry of biosimilars and generics.
Price negotiations and reimbursement policies.
Patent litigation delaying generic entry.
Key Takeaways
NDC 60505-0249 (Sutent) holds a leading position in targeted oncology therapy.
The market is competitive, dominated by Pfizer, with major competitors including Pazopanib and Axitinib.
The market size is projected around US$1.2–1.4 billion in the next few years.
Price per mg is expected to decline post-2027 due to patent expiration and biosimilar entry.
Competitive pressures and reimbursement strategies will significantly influence future sales and pricing.
FAQs
When is patent expiration for Sutent expected?
Around 2027 in major markets, opening the door for biosimilars and generics.
What are key competitors for Sutent?
Pazopanib, Axitinib, and Lenvatinib.
How is the market share split among drugs in this category?
Sunitinib holds roughly 45%, with Pazopanib at 20%, and others filling smaller segments.
What impact will biosimilars have?
Likely a 50-70% price reduction and increased market competition after patent expiry.
How do regulatory changes affect pricing?
Reimbursement policies and negotiated discounts can lower net prices; approvals for new indications could expand market size.
References
IQVIA. (2023). Global Oncology Drug Market Overview.
U.S. Food and Drug Administration. (2022). Sunitinib Approval and Indications.
EvaluatePharma. (2022). Oncology Market Data.
PubChem. (2023). Sunitinib (NDC 60505-0249) Chemical Profile.
FDA. (2022). Patent and Exclusivity Data for Sutent.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
